Ampliação de uso dos medicamentos antirretrovirais dolutegravir (DTG) e darunavir (DRV), já disponibilizados pelo Ministério da Saúde para o tratamento da infecção pelo HIV

Brasil. Ministério da Saúde. Comissão Nacional de Incorporação de Tecnologias no SUS.
Brasília; CONITEC; set. 2016. ilus.
Monografia Português | LILACS, BRISA | ID: biblio-837252

Documentos relacionados

  1. Pharmacokinetic Outcomes of the Interactions of Antiretroviral Agents with Food and Supplements: A Systematic Review and Meta-Analysis.
  2. Plasma Concentrations of Rosmarinic Acid in Patients on Antiretroviral Therapy: In Silico Exploration Based on Clinical Data.
  3. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
  4. Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability.
  5. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
  6. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype.
  7. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
  8. Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
  9. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
  10. Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.